A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products

Peritoneal Dialysis International

Volumn 32, Issue 3, 2012, Pages 280-291

  Lai, Kar Neng ^a   Lam, Man Fai ^a   Leung, Joseph C K ^a   Chan, Loretta Y ^a   Lam, Christopher W K ^b   Chan, Iris H S ^b   Chan, Hoi Wong ^c   Li, Chun Sang ^c   Wong, Sunny S H ^d   Ho, Yiu Wing ^d   Cheuk, Au ^e   Tong, Matthew K L ^e   Tang, Sydney C W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^d UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^e PRINCESS MARGARET HOSPITAL   (Hong Kong)

Author keywords

Adipokines; Cardiovascular event; Chemokines; Glucose degradation products; Low GDP dialysate

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; GLUCOSE DEGRADATION PRODUCT; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PERITONEAL DIALYSIS FLUID; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BIOASSAY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOKINE PRODUCTION; DIALYSATE; DIALYSATE LEVEL; DOWN REGULATION; FEMALE; GLOMERULUS FILTRATION; HOMEOSTASIS; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; SURVIVAL RATE; TREATMENT DURATION; URINE VOLUME;

EID: 84861685155     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2010.00176     Document Type: Article

References (45)

1. Brownlee M, Cerami A, Vlassara H. Advanced glycation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318:1315-21.
2. Nakamura S, Tachikawa T, Tobita K, Miyazaki S, Sakai S, Morita T, et al. Role of advanced glycation end products and growth factors in peritoneal dysfunction in CAPD patients. Am J Kidney Dis 2003; 41(Suppl 1):S61-7.
3. Chaudhary K, Khanna R. Biocompatible peritoneal dialysis solutions: do we have one? Clin J Am Soc Nephrol 2010; 5:723-32.
4. Lee HY, Choi HY, Park HC, Seo BJ, Do JY, Yun SR, et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006; 21:2893-9.
5. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25:48-55.
6. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
7. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
8. Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22:552-9.
9. Do JY, Kim YL, Park JW, Chang KA, Lee SH, Ryu DH, et al. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis. Perit Dial Int 2008; 28(Suppl 3):S101-6.
10. Kim S, Oh J, Kim S, Chung W, Ahn C, Kim SG, et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009; 24:2899-908.
11. Lai KN, Lo WK. Optimal peritoneal dialysis for patients from Hong Kong. Perit Dial Int 1999; 19(Suppl 3):S26-31.
12. van Olden RW, Krediet RT, Struijk DG, Arisz L. Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1996; 7:745-50.
13. Nolph KD, Moore HL, Twardowski ZJ, Khanna R, Prowant B, Meyer M, et al. Cross-sectional assessment of weekly urea and creatinine clearances in patients on continuous ambulatory peritoneal dialysis. ASAIO J 1992; 38:M139-42.
14. Zemel D, Imholz AL, de Waart DR, Dinkla C, Struijk DG, Krediet RT. Appearance of tumor necrosis factor-alpha and soluble TNF-receptorsI and II in peritoneal effluent of CAPD. Kidney Int 1994; 46:1422-30.
15. Jörres A. Glucose degradation products in peritoneal dialysis: from bench to bedside. Kidney Blood Press Res 2003; 26:113-17.
16. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14:1541-9.
17. Lai KN, Leung JC, Chan LY, Li FF, Tang SC, Lam MF, et al. Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products. Clin Exp Immunol 2004; 138:466-75.
18. Leung JC, Chan LY, Li FF, Tang SC, Chan KW, Chan TM, et al. Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGF. Nephrol Dial Transplant 2005; 20:1336-49.
19. Oh EJ, Ryu HM, Choi SY, Yook JM, Kim CD, Park SH, et al. Impact of low glucose degradation product bicarbonate/ lactate-buffered dialysis solution on the epithelialmesenchymal transition of peritoneum. Am J Nephrol 2010; 31:58-67.
20. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, et al. on behalf of the FHN Trial Group. Incenter hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363:2287-300. [Erratum in: N Engl J Med 2011; 364:93]
21. Fusshöller A, Plail M, Grabensee B, Plum J. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant 2004; 19:2101-6.
22. Choi HY, Kim DK, Lee TH, Moon SJ, Han SH, Lee JE, et al. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Perit Dial Int 2008; 28:174-82.
23. Weiss L, Stegmayr B, Malmsten G, Tejde M, Hadimeri H, Siegert CE, et al. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 2009; 29:647-55.
24. Fang W, Mullan R, Shah H, Mujais S, Bargman JM, Oreopoulos DG. Comparison between bicarbonate/lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: a prospective, crossover single-dwell study. Perit Dial Int 2008; 28:35-43.
25. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73:200-6.
26. Pajek J, Kveder R, Bren A, Gucek A, Bucar M, Skoberne A, et al. Short-term effects of bicarbonate/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study. Nephrol Dial Transplant 2009; 24:1617-25.
27. Haag-Weber M, Krämer R, Haake R, Islam MS, Prischl F, Haug U, et al. Low-GDP fluid (Gambrosol Trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant 2010; 25:2288-96.
28. Martikainen TA, Teppo AM, Grönhagen-Riska C, Ekstrand AV. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 2005; 25:453-60.
29. Pajek J, Kveder R, Bren A, Gucek A, Ihan A, Osredkar J, et al. Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study. Perit Dial Int 2008; 28:44-52.
30. Topley N, Brown Z, Jörres A, Westwick J, Davies M, Coles GA, et al. Human peritoneal mesothelial cells synthesize interleukin-8. Synergistic induction by interleukin1beta and tumor necrosis factor-alpha. Am J Pathol 1993; 142:1876-86.
31. Leung JC, Chan LY, Tam KY, Tang SC, Lam MF, Cheng AS, et al. Regulation of CCN2/CTGF and related cytokines in cultured peritoneal cells under conditions simulating peritoneal dialysis. Nephrol Dial Transplant 2009; 24:458-69.
32. Yu MA, Shin KS, Kim JH, Kim YI, Chung SS, Park SH, et al. HGF and BMP-7 ameliorate high glucose-induced epitheli-al-to-mesenchymal transition of peritoneal mesothelium. J Am Soc Nephrol 2009; 20:567-81.
33. Ikeda Y, Murakami A, Fujimura Y, Tachibana H, Yamada K, Masuda D, et al. Aggregated ursolic acid, a natural triterpenoid, induces IL-1beta release from murine peritoneal macrophages: role of CD36. J Immunol 2007; 178:4854-64.
34. Leung JC, Chan LY, Tang SC, Chu KM, Lai KN. Leptin induces TGF-beta synthesis through functional leptin receptor expressed by human peritoneal mesothelial cell. Kidney Int 2006; 69:2078-86.
35. Witowski J, Tayama H, Ksiazek K, Wanic-Kossowska M, Bender TO, Jörres A. Human peritoneal fibroblasts are a potent source of neutrophil-targeting cytokines: a key role of IL-1beta stimulation. Lab Invest 2009; 89:414-24.
36. Teta D, Maillard M, Tedjani A, Passlick-Deetjen J, Burnier M. The effect of pH-neutral peritoneal dialysis fluids on adipokine secretion from cultured adipocytes. Nephrol Dial Transplant 2007; 22:862-9.
37. Axelsson J, Rashid Qureshi A, Suliman ME, Honda H, Pecoits-Filho R, Heimbürger O, et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004; 80:1222-9.
38. Xu L, Jiang CQ, Lam TH, Lin JM, Yue XJ, Cheng KK, et al. The metabolic syndrome is associated with subclinical atherosclerosis independent of insulin resistance: the Guangzhou Biobank Cohort Study-CVD. Clin Endocrinol (Oxf) 2010; 73:181-8.
39. Teta D, Maillard M, Halabi G, Burnier M. The leptin/ adiponectin ratio: potential implications for peritoneal dialysis. Kidney Int Suppl 2008; (108):S112-18.
40. Lai KN, Leung JC. Inflammation in peritoneal dialysis. Nephron Clin Pract 2010; 116:c11-18.
41. Han SH, Choi HY, Kim DK, Moon SJ, Lee JE, Yoo TH, et al. Elevated cardiac troponinT predicts cardiovascular events in asymptomatic continuous ambulatory peritoneal dialysis patients without a history of cardiovascular disease. Am J Nephrol 2009; 29:129-35.
42. Paniagua R, Amato D, Mujais S, Vonesh E, Ramos A, Correa-Rotter R, et al. Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial. Clin J Am Soc Nephrol 2008; 3:407-15.
43. Lam MF, Tang C, Wong AK, Tong KL, Yu AW, Li CS, et al. ASPD: a prospective study of adequacy in Asian patients on long term, small volume, continuous ambulatory peritoneal dialysis. Perit Dial Int 2006; 26:466-74.
44. Nichols J, Going S, Loftin M, Stewart D, Nowicki E, Pickrel J. Comparison of two bioelectrical impedance analysis instruments for determining body composition in adolescent girls. Int J Body Compos Res 2006; 4:153-60.
45. Woodrow G. Body composition analysis techniques in adult and pediatric patients: how reliable are they? How useful are they clinically? Perit Dial Int 2007; 27(Suppl 2):S245-9.